HABA LaboratoriesInc Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Issei Miyazaki

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	3.1yrs
Participación del CEO	n/a
Permanencia media de la dirección	3.1yrs
Promedio de permanencia en la Junta Directiva	4.9yrs

Actualizaciones recientes de la dirección

Recent updates

What Type Of Returns Would HABA LaboratoriesInc's(TYO:4925) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

Mar 09

These 4 Measures Indicate That HABA LaboratoriesInc (TYO:4925) Is Using Debt Reasonably Well

Feb 19

Should You Be Impressed By HABA LaboratoriesInc's (TYO:4925) Returns on Capital?

Feb 01

Is HABA Laboratories,Inc. (TYO:4925) A Smart Choice For Dividend Investors?

Jan 13

HABA Laboratories,Inc.'s (TYO:4925) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

Dec 25

What Kind Of Investors Own Most Of HABA Laboratories,Inc. (TYO:4925)?

Dec 07

A Look At HABA LaboratoriesInc's (TYO:4925) Share Price Returns

Nov 19

CEO

Issei Miyazaki (65 yo)

3.1yrs

Permanencia

Issei Miyazaki is President, CEO, MD & Director of HABA Laboratories,Inc. from April 2021. Issei Miyazaki joined the HABA Laboratories,Inc.in October 2013.

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Noriko Koyanagi	Executive Chairman	8.9yrs	sin datos	0.56% ¥ 43.6m
Issei Miyazaki	President	3.1yrs	sin datos	sin datos
Yoshinori Nishimura	In charge of Food Dev.	less than a year	sin datos	sin datos

3.1yrs

Permanencia media

65yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 4925 se considera experimentado (3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Noriko Koyanagi	Executive Chairman	8.9yrs	sin datos	0.56% ¥ 43.6m
Issei Miyazaki	President	3.1yrs	sin datos	sin datos
Yoshinori Nishimura	In charge of Food Dev.	3.9yrs	sin datos	sin datos
Tsunekazu Umeda	Independent Outside Director	8.9yrs	sin datos	0.53% ¥ 41.5m
Noriyasu Komata	Independent Outside Director	no data	sin datos	sin datos
Tomotaka Matsui	Director	2.9yrs	sin datos	sin datos
Keizo Shibata	Director	no data	sin datos	sin datos
Yoshiko Arikawa	Independent Outside Director	6.9yrs	sin datos	sin datos
Kayoko Yamato	Independent Outside Director	4.9yrs	sin datos	sin datos

4.9yrs

Permanencia media

65yo

Promedio de edad

Junta con experiencia: La junta directiva de 4925 se considera experimentada (4.8 años de antigüedad promedio).

HABA LaboratoriesInc Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

HABA Laboratories,Inc., Annual General Meeting, Jun 23, 2024

HABA Laboratories,Inc., Annual General Meeting, Jun 18, 2023

Less than half of directors are independent

HABA Laboratories,Inc., Annual General Meeting, Jun 19, 2022

Less than half of directors are independent

Recent updates

Full year 2024 earnings released: JP¥560 loss per share (vs JP¥187 loss in FY 2023)

HABA Laboratories,Inc., Annual General Meeting, Jun 23, 2024

HABA Laboratories,Inc. to Report Fiscal Year 2024 Results on May 10, 2024

Upcoming dividend of JP¥40.00 per share

Third quarter 2024 earnings released: JP¥150 loss per share (vs JP¥153 loss in 3Q 2023)

HABA Laboratories,Inc. to Report Q3, 2024 Results on Feb 09, 2024

Second quarter 2024 earnings released: JP¥34.38 loss per share (vs JP¥23.80 loss in 2Q 2023)

HABA Laboratories,Inc. to Report Q2, 2024 Results on Nov 10, 2023

First quarter 2024 earnings released: JP¥56.86 loss per share (vs JP¥37.02 loss in 1Q 2023)

HABA Laboratories,Inc. to Report Q1, 2024 Results on Aug 10, 2023

Full year 2023 earnings released: JP¥187 loss per share (vs JP¥71.14 loss in FY 2022)

Full year 2023 earnings released: JP¥187 loss per share (vs JP¥71.14 loss in FY 2022)

HABA Laboratories,Inc., Annual General Meeting, Jun 18, 2023

Upcoming dividend of JP¥40.00 per share at 1.7% yield

Third quarter 2023 earnings released: JP¥153 loss per share (vs JP¥17.19 loss in 3Q 2022)

HABA Laboratories,Inc. to Report Q3, 2023 Results on Feb 10, 2023

Second quarter 2023 earnings released: JP¥23.80 loss per share (vs JP¥49.98 loss in 2Q 2022)

Less than half of directors are independent

Second quarter 2023 earnings released: JP¥23.80 loss per share (vs JP¥49.98 loss in 2Q 2022)

HABA Laboratories,Inc. to Report Q2, 2023 Results on Nov 11, 2022

First quarter 2023 earnings released: JP¥37.02 loss per share (vs JP¥72.72 loss in 1Q 2022)

Haba Laboratories Ordinary Shares to Be Deleted from Other OTC

Full year 2022 earnings released: JP¥71.14 loss per share (vs JP¥57.12 profit in FY 2021)

HABA Laboratories,Inc. to Report Q1, 2023 Results on Aug 12, 2022

Full year 2022 earnings released: JP¥71.14 loss per share (vs JP¥57.12 profit in FY 2021)

HABA Laboratories,Inc., Annual General Meeting, Jun 19, 2022

Less than half of directors are independent

HABA Laboratories,Inc. to Report Fiscal Year 2022 Results on May 11, 2022

Upcoming dividend of JP¥40.00 per share

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Second quarter 2022 earnings released: JP¥49.98 loss per share (vs JP¥1.59 loss in 2Q 2021)

First quarter 2022 earnings released: JP¥72.72 loss per share (vs JP¥51.57 loss in 1Q 2021)

Full year 2021 earnings released: EPS JP¥57.12 (vs JP¥339 in FY 2020)

Full year 2021 earnings released: EPS JP¥57.12 (vs JP¥339 in FY 2020)

Upcoming dividend of JP¥40.00 per share

What Type Of Returns Would HABA LaboratoriesInc's(TYO:4925) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

New 90-day high: JP¥4,515

These 4 Measures Indicate That HABA LaboratoriesInc (TYO:4925) Is Using Debt Reasonably Well

Third quarter 2021 earnings released: EPS JP¥30.15 (vs JP¥42.27 in 3Q 2020)

New 90-day high: JP¥4,350

Should You Be Impressed By HABA LaboratoriesInc's (TYO:4925) Returns on Capital?

Is HABA Laboratories,Inc. (TYO:4925) A Smart Choice For Dividend Investors?

HABA Laboratories,Inc. to Report Q3, 2021 Results on Feb 12, 2021

HABA Laboratories,Inc.'s (TYO:4925) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

What Kind Of Investors Own Most Of HABA Laboratories,Inc. (TYO:4925)?

A Look At HABA LaboratoriesInc's (TYO:4925) Share Price Returns

Second quarter 2021 earnings released: JP¥1.59 loss per share

New 90-day low: JP¥4,055

HABA Laboratories,Inc. to Report Q2, 2021 Results on Nov 11, 2020

First quarter earnings released

New 90-day low - JP¥4,060

CEO

Permanencia

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad